Low-grade oligodendroglioma: current treatments and future hopes (Q37628706)

21 August 2017

1 reference

title

Low-grade oligodendroglioma: current treatments and future hopes (English)

1 reference

21 August 2017

1 reference

adult oligodendroglioma

1 reference

Zarnie Lwin

1

1 reference

21 August 2017

Hui K Gan

series ordinal

2

1 reference

21 August 2017

Warren P Mason

series ordinal

3

1 reference

21 August 2017

publication date

1 November 2009

1 reference

Expert Review of Anticancer Therapy

21 August 2017

published in

1 reference

21 August 2017

volume

9

1 reference

21 August 2017

issue

11

1 reference

21 August 2017

page(s)

1651-1661

1 reference

Invited article: the expanding impact of molecular biology on the diagnosis and treatment of gliomas

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Low grade glial neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

The changing management of low-grade astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Low-grade glioma: supratentorial astrocytoma, oligodendroglioma, and oligoastrocytoma in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Long-term outcome of low-grade oligodendroglioma and mixed glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Long-term outcome of oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Procarbazine, lomustine, and vincristine (PCV) chemotherapy for grade III and grade IV oligoastrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Oligodendroglioma: incidence and biological behavior in a defined population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Molecular pathology and clinical characteristics of oligodendroglial neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Temozolomide single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Interobserver variability in determining MIB-1 labeling indices in oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Prognostic and survival-related factors in patients with well-differentiated oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Low-grade oligodendroglioma: an indolent but incurable disease? Clinical article

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

21 January 2018

Glioma therapy in adults

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Diffusely infiltrative low-grade gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Prognostic factors in low grade (WHO grade II) gliomas of the cerebral hemispheres: the role of surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Radiotherapy in low-grade gliomas: pros

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Current diagnosis and treatment of oligodendroglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

The dose-volume interaction in adult supratentorial low-grade glioma: higher radiation dose is beneficial among patients with partial resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Hyperfractionated radiation therapy for incompletely resected supratentorial low-grade glioma: a 10-year update of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Can chemotherapy replace radiotherapy in low-grade gliomas? Time for randomized studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Low-grade oligodendroglioma responds to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Chemotherapy of low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Recent developments in the use of chemotherapy in brain tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Phase II trial of temozolomide in patients with progressive low-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Phase II study of protracted daily temozolomide for low-grade gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Toxicity and efficacy of protracted low dose temozolomide for the treatment of low grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

Outcome in adult low-grade glioma: the impact of prognostic factors and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.127

21 January 2018

Identifiers

DOI

10.1586/ERA.09.127

1 reference

21 August 2017

1 reference